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ORIGINAL ARTICLE
Effects of dexmedetomidine infusion during spinal anesthesia on
hemodynamics and sedation
Ebru Tarıkçı Kılıça and Gaye Aydınb
aAnesthesiology Department, Ümraniye Training and Research Hospital, İstanbul, Turkey; bAnesthesiology Department, Tepecik Training
and Research Hospital, İzmir, Turkey
ABSTRACT
Background: We evaluated the effects of intravenous dexmedetomidine during spinal
anesthesia on hemodynamics, respiratory rate, oxygen saturation, sedpain, and compared
them with those of saline infusion. Sixty American Society of Anesthesiologists physical status
I and II cases were randomly divided into two groups. Patients were connected to the monitor
after premedication, and spinal anesthesia was administered. Sensory and motor blockades
were assessed using pinprick test and Bromage scale, respectively. Group I received dexme-
detomidine infusion and Group II received saline infusion. Throughout the infusion process,
hemodynamic data, respiratory rate, oxygen saturation, sedation, pain, Bromage score,
amnesia, bispectral index, and side effects were recorded. Postoperative hemodynamic
measurements, oxygen saturation, sedation, pain scores were obtained. Sedation and pain
were evaluated using the Ramsay and visual analog scales, respectively. Analgesics were
administered in cases with high scores on the visual analog scale. Postoperative analgesic
consumption, side effects, treatments were recorded. No significant differences were found
between the groups with respect to oxygen saturation, respiratory rate, pain, and side effects
in the intraoperative period. Time to onset of sensorial block, maximum sensorial block, onset
of motor block, and maximum motor block; bispectral index values; and apex heartbeat until
80 min of infusion, systolic arterial blood pressure until 90 min, and diastolic arterial blood
pressure until 50 min were lower, whereas amnesia and sedation levels were higher in
dexmedetomidine group. Postoperative pain and analgesic requirement were not different.
Apex heartbeat at 15 min and systolic arterial blood pressure at 30 min were lower and
sedation scores were higher in the dexmedetomidine infusion group. We demonstrated
dexmedetomidine infusion had a hemodynamic depressant effect intraoperatively whereas
it had no significant effect on peripheral oxygen saturation, respiratory rate, visual analog
scale scores, and side effects. Dexmedetomidine infusion enhanced motor and sensory
blockade quality and induced amnesia and sedation.
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Regional anesthesia has several important advan-
tages: it does not obtund normal reflexes such as
coughing and swallowing, it does not affect respira-
tion, its effects continue in the postoperative period, it
is associated with lower costs and a shorter length of
hospital stay, and it has been administered success-
fully almost in all surgical branches [1].
Thus, today, low-risk regional anesthesia techni-
ques are widely preferred in the treatment of local
lesions in various parts of the body because the tech-
niques are easy to perform, their effects last for
shorter periods of time, they minimize the anxiety of
the patient, and sufficient anesthesia is adminstered
in the surgical field. Conscious sedation is a technique
during which the patient cooperates and is able to
follow the commands, even if they may be slightly
obtunded; however, the patient does not realize the
incidents during surgery and postoperatively while
the sensory and motor functions are preserved.
Administering sedation through local procedures for
diagnostic and treatment purposes is recommended
both to facilitate surgery at the surgeon’s end and to
ensure the patient’s comfort [1,2].
Studies have demonstrated that α2 agonists produce
sympatholytic effects and dose-dependent analgesia
and sedation, and attenuate neuroendocrine and hemo-
dynamic responses related to surgery and anesthesia.
These characteristics suggest that dexmedetomidine,
which is an α2 receptor agonist, is theoretically an
appropriate agent for use in anesthesia [3]. Moreover,
reduction of opioid requirements and lack of respiratory
depression are other advantages of dexmedetomidine
with regard to its use in monitored anesthesia [2,4].
In the present study, we aimed to investigate the
effects of intravenous dexmedetomidine infusion on
sedation, analgesia, amnesia, spinal anesthesia (block
quality), and hemodynamics in varicocelectomy, orch-
iectomy, inguinal hernia, and lower-extremity
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operations, including soft-tissue surgeries, in cases
where spinal anesthesia is administered with the pur-
pose of monitored anesthesia care.
2. Materials and methods
After obtaining the approval of the Ethics Committee
and consent of the patients, the study was conducted
in the Department of Anesthesiology at Trakya
University Faculty of Medicine. We included 60
American Society of Anesthesiologists physical status
I and II cases aged between 18 and 45 years who were
to undergo inguinal hernia, varicocelectomy, orchiect-
omy, hemorrhoidectomy, anal fissure, or soft-tissue
surgery. Patients with a medical history of opioid
and warfarin use, abnormalities in coagulation tests,
lumbar vertebral anomalies, neurological disorders, or
infections and those under the age of 18 years were
excluded from the study.
Atropine (0.015 mg kg−1; atropine sulfate ampoule
1 mg mL−1, Galen Pharmaceutical Ind. and Trade Inc.,
Istanbul,Turkey) plus midazolam (0.07 mg kg−1;
Dormicum ampoule 5 mg mL−1, Roche
Pharmaceutical Ind. and Trade Inc., Istanbul,Turkey)
were administered 45 min prior to procedure for pre-
medication. A peripheral vascular line was inserted in
all subjects, lactate infusion of 10 mL kg−1 was
initiated, and prophylactic antibiotics were adminis-
tered through the same vascular line.
The cases were randomly divided into two groups
comprising equal numbers of patients. Group I received
IV dexmedetomidine (Precedex vial 200 μg mL−1,
Abbott Pharmaceutical Ind. and Trade Inc., North
Chicago, USA) infusion at a rate of 0.2 μg kg−1 h−1 for
sedation simultaneously with spinal anesthesia. Control
patients in Group II received IV saline infusion at a rate of
0.5 mg kg−1 h−1 simultaneously with spinal anesthesia.
After patients were placed on the operating table,
systolic blood pressure (SAP), diastolic blood pressure
(DAP), and apex beat of the heart (ABH), respiratory rate
per minute (RR), peripheral oxygen saturation (SpO2),
sedation and amnesia scores, and bispectral index (BIS)
and visual analog scale (VAS) scores were recorded prior
to intrathecal injection. Following skin preparation and
covering in line with the rules of antisepsis, all patients
were informed about each phase of the procedure. After
the cutaneous–subcutaneous injection of 2 mL of 2%
lidocaine (Jetosel ampoule 20 mg 2 mL−1, Biosel
Pharmaceutical Ind. and Trade Inc., İstanbul), into the
subarachnoid space from the L2-3 or L3-4 site via a 22G
needle by median approach and upon detecting that
cerebrospinal fluid was released from the same space,
spinal anesthesia was administered by injecting 3 mL
(15 mg) of bupivacaine (Marcaine heavy, 15 mg 5 mL−1,
Astra Zeneca Pharmaceutical Ind. and Trade Inc.,
İstanbul, Turkey) SAP, DAP, ABH values, RR, SpO2, seda-
tion and amnesia scores, as well as BIS and VAS levels
were recorded at 1, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80,
and 90 min of dexmedetomidine infusion. The time to
onset of sensory and motor blockade, duration of sen-
sory and motor blockade, level of maximum sensory
blockade, and Bromage scores were recorded. Motor
blockade was evaluated using the Bromage scale [5],
and sensory blockade was evaluated using the pinprick
test. Sedation was evaluated using the Ramsay Sedation
Scale [6]. Prior to the onset of medication infusion, three
images were shown to the subjects. Their amnesia
scores were evaluated prior and subsequent to the
administration of anesthesia. Remembering the content
and subject of each image was rated as 1 point. The
scoring comprised 0–6 points. The infusion rate of the
medication was set so as to maintain the BIS score at a
level of 60–80. The values of 0–40 were regarded as
deep hypnotic state, 40–60 as mild hypnotic, 60–80 as
lower limit of awareness, and 80–100 as awareness [7].
VAS was used to assess pain. The leftmost value on the
10-cm horizontal line represented no pain, and the
rightmost value represented severe pain. The subjects
indicated their levels of pain using this line [8].
At the postoperative (when the subjects were taken
to the recovery room following the administration of
anesthesia) 5, 15, 30, 45, 60, and 120 min and 2, 4, 6, 12,
24 h, pain was assessed using VAS, and SAP, DAP, SpO2,
ABH, and sedation score and initial analgesic require-
ments were recorded. In addition, we documented the
side effects and complications such as hypotension and
bradycardia induced by the medications as well as addi-
tional treatments that were used in the study.
In subjects with postoperative pain scores equal to
and higher than 4, 8 mg of lornoxicam (Xefo vial
8 mg, Abdi İbrahim Pharmaceutical Ind. and Trade
Inc., İstanbul) was administered intravenously.
Additional doses of analgesics were recorded.
The scores were presented as mean ± SD or mean
(min–max). The Kolmogorov–Smirnov test was used
to test whether the quantitative variables were nor-
mally distributed. In the comparison between the two
groups, the t-test was used to assess normally distrib-
uted variables in independent groups, whereas the
Mann–Whitney U-test was used to assess non-nor-
mally distributed variables. A p value of <0.05 was
considered statistically significant. The STATISTICA
7.0 (License Code: 31N6YUCV38) package program
was used for statistical analysis.
3. Results
Table 1 shows demographic and anthropometric data
and operating times of the groups. When the intrao-
perative systolic arterial pressure (SAP) was evaluated
between the groups, there was a statistically significant
difference at 1, 5, 10, 15, 20, 30, 40, 50, 60, 70, and 80min
of infusion (p < 0.001, p < 0.001, p < 0.001, p < 0.001,
p < 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.003,
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p < 0.007, and p < 0.028, respectively). In terms of
intraoperative DAP values between the groups, there
was a statistically significant difference with respect to
values at 1, 5, 10, 15, 20, 30, and 40 min of infusion
(p < 0.001, p < 0.024, p < 0.001, p < 0.001, p < 0.001,
p < 0.002, and p < 0.034, respectively). In addition, a
statistically significant difference was found between
the groups at 1, 5, 10, 15, 20, 30, 40, 50, 60, and 70 min
with respect to the intraoperative ABH scores (p < 0.031,
p < 0.019, p < 0.001, p < 0.001, p < 0.001, p < 0.001,
p < 0.023, p < 0.006, p < 0.006, and p < 0.028, respec-
tively) (Figures 1–3).
There was no statistically significant difference
between the groups in terms of intraoperative RR
(p > 0.05). Similarly, no statistically significant differ-
ence was found between intraoperative oxygen
saturation levels (SpO2) for the two groups (p > 0.05).
Intraoperative Ramsay sedation scores of the groups
are shown in Table 2. There was a statistically significant
difference between the groups at 1, 5, 10, 15, 20, 30, 40,
50, 60, 70, 80, and 90 min of dexmedetomidine infusion
(p < 0.023, p < 0.001, p < 0.001, p < 0.001, p < 0.001,
p < 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.001,
p < 0.001, and p < 0.033, respectively).
Table 3 demonstrates the intraoperative amnesia
scores of the groups. There was a statistically signifi-
cant difference between the groups at 1, 5,10, 15, 20,
30, 40, 50, 60, 70, 80, and 90 min of dexmedetomidine
infusion (p < 0.001, p < 0.001, p < 0.001, p < 0.001,
p < 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.001,
p < 0.001, p < 0.001, and p < 0.006, respectively).
Intraoperative BIS scores of the groups are shown
in Table 4. There was a statistically significant differ-
ence between the groups at 1, 5, 10, 15, 20, 30, 40, 50,
60, 70, and 80 min of dexmedetomidine infusion
(p < 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.001,
p < 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.001,
and p < 0.005, respectively).
Comparison of intraoperative VAS values of the groups
revealed no statistically significant difference (p > 0.05).
There was a statistically significant difference
between the groups at 5 min of dexmedetomidine
infusion with respect to Bromage scores (p < 0.003).
In terms of intraoperative side effects, no statisti-
cally significant difference was found between the
groups (p > 0.05). Nausea occurred in three cases in
Group I and 2 cases in Group II, whereas bradycardia
occurred in three cases in Group I and none of the
cases in Group II. Hypotension was encountered in
one case in Group I and none of the cases in Group
II. However, there was no statistically significant
Table 1. Demographic and antropometric data of groups,




(n = 30) p
Year (age) 29.83 ± 9.01 34.23 ± 9.84 0.086
Weight (kg) 74.43 ± 10.75 72.60 ± 12.65 0.529
Durations of operations
(min)
49.67 ± 21.08 59.83 ± 25.54 0.076

































































dexmedtomidine administered postoperative %0,9 NaCl administered postoperative
dexmedtomidine administered intraoperative %0,9 NaCl administered intraoperative
Figure 1. Comparison of the SAP values.




























































Dexmedetomidine administered intraoperative %0.9 NaCl administered intraoperative
Dexmedetomidine administered postoperative %0.9 NaCl administered posoperative




















































Dexmedetomidine administered intraoperative %0.9 NaCl administered intraoperative
Dexmedetomidine administered postoperative %0.9 NaCl administered posoperative
Figure 3. Comparison of the HR.
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difference between the groups with respect to intrao-
perative side effects (p > 0.05).
The mean time to onset of sensory blockade was
2.90 ± 1.47 min in Group I (range 1–8) and
5.00 ± 2.66 min in Group II (range 2–12). Therefore,
there was a statistically significant difference between
the groups in this aspect (p = 0.001). The mean time of
cessation of the sensory blockade was found to be
131.77 ± 27.09 in Group I (105–232) and
124.80 ± 26.77 in Group II (68–180). No statistically sig-
nificant difference was found between the groups
(p = 0.478). The mean time to maximum sensory block-
ade was 11.30 ± 7.48 in Group I (2–45) and 20.20 ± 37.99
in Group II. There was a statistically significant difference
between the groups (p = 0.007) (Table 5).
The mean time to onset of motor blockade was
5.27 ± 3.50 (1–20) in Group I and 8.83 ± 6.10 in Group
II (2–25), and there was a statistically significant
Table 2. Ramsay sedation scores of the groups (min–max).
Timing Group I (n = 30) Group II (n = 30) p
Before intratechal injection 1.83 ± 0.37 (1–2) 1.97 ± 0.18 (1–2) 0.088
After intratechal injection 1.90 ± 0.30 (1–2) 1.97 ± 0.18 (1–2) 0.305
Before dex.infusion 2.00 ± 0.26 (1–3) 1.97 ± 0.18 (1–2) 0.570
1st.min dex.infusion 2.27 ± 0.52 (2–4) 2.03 ± 0.18 (2–3) 0.023*
5th.min dex.infusion 2.47 ± 0.62 (2–4) 2.07 ± 0.36 (2–4) 0.001*
10th.min dex.infusion 2.63 ± 0.71 (2–4) 2.07 ± 0.36 (2–4) 0.001*
15th.min dex.infusion 2.77 ± 0.77 (2–4) 2.07 ± 0.36 (2–4) 0.001*
20th.min dex.infusion 3.03 ± 0.77 (2–4) 2.08 ± 0.39 (2–4) 0.001*
30th.min dex.infusion 3.03 ± 0.86 (2–5) 2.12 ± 0.44 (2–4) 0.001*
40th.min dex.infusion 3.11 ± 0.90 (2–5) 2.12 ± 0.44 (2–4) 0.001*
50th.min dex.infusion 2.76 ± 0.83 (2–4) 2.05 ± 0.21 (2–3) 0.001*
60th.min dex.infusion 2.73 ± 0.78 (2–4) 2.00 ± 0.00 (2–2) 0.001*
70th.min dex.infusion 2.67 ± 0.51 (2–3) 2.00 ± 0.00 (2–2) 0.001*
80th.min dex.infusion 3.00 ± 0.70 (2–4) 2.00 ± 0.00 (2–2) 0.001*
90th.min dex.infusion 2.67 ± 0.57 (2–3) 2.00 ± 0.00 (2–2) 0.033*
*p < 0.05; significant difference between the groups.
Table 3. Amnesia scores between the groups (min–max).
Timing Group I (n = 30) Group II (n = 30) p
Before intratechal injection 5.97 ± 0.18 (5–6) 6.00 ± 0.00 (6–6) 0.317
After intratechal injection 5.90 ± 0.54 (3–6) 6.00 ± 0.00 (6–6) 0.317
Before dex.infusion 5.90 ± 0.54 (3–6) 6.00 ± 0.00 (6–6) 0.317
1st.min dex.infusion 5.30 ± 1.14 (2–6) 6.00 ± 0.00 (6–6) <0.001*
5th.min dex.infusion 4.67 ± 1.29 (2–6) 6.00 ± 0.00 (6–6) <0.001*
10th.min dex.infusion 4.30 ± 1.23 (2–6) 6.00 ± 0.00 (6–6) <0.001*
15th.min dex.infusion 3.70 ± 1.23 (2–6) 6.00 ± 0.00 (6–6) <0.001*
20th.min dex.infusion 3.47 ± 1.04 (2–6) 6.00 ± 0.00 (6–6) <0.001*
30th.min dex.infusion 3.34 ± 1.11 (2–6) 6.00 ± 0.00 (6–6) <0.001*
40th.min dex.infusion 3.22 ± 1.16 (2–6) 6.00 ± 0.00 (6–6) <0.001*
50th.min dex.infusion 3.06 ± 1.19 (2–6) 6.00 ± 0.00 (6–6) <0.001*
60th.min dex.infusion 2.91 ± 1.04 (2–5) 6.00 ± 0.00 (6–6) <0.001*
70th.min dex.infusion 2.83 ± 0.98 (2–4) 6.00 ± 0.00 (6–6) <0.001*
80th.min dex.infusion 3.00 ± 1.00 (2–4) 6.00 ± 0.00 (6–6) <0.001*
90th.min dex.infusion 3.00 ± 1.00 (2–4) 6.00 ± 0.00 (6–6) 0.006*
*p < 0.05; significant difference between the groups.
Table 4. BIS analysis between the groups (min–max).
Timing Group I (n = 30) Group II (n = 30) p
Before intratechal injection 92.13 ± 4.98 (82–99) 93.20 ± 3.69 (88–99) 0.433
After intratechal injection 91.80 ± 4.55 (82–98) 92.67 ± 3.73 (84–98) 0.591
Before dex.infusion 91.00 ± 5.25 (80–99) 93.70 ± 3.94 (86–98) 0.053
1st.min dex.infusion 85.40 ± 7.85 (66–98) 92.43 ± 3.58 (84–98) 0.001*
5th.min dex.infusion 79.37 ± 8.07 (65–96) 91.20 ± 3.76 (79–98) 0.001*
10th.min dex.infusion 74.90 ± 8.19 (63–92) 90.97 ± 4.79 (80–99) 0.001*
15th.min dex.infusion 71.77 ± 6.86 (60–85) 89.93 ± 6.83 (70–98) 0.001*
20th.min dex.infusion 70.57 ± 6.55 (60–84) 88.96 ± 8.07 (62–97) 0.001*
30th.min dex.infusion 69.55 ± 6.57 (60–82) 89.04 ± 7.47 (62–98) 0.001*
40th.min dex.infusion 70.17 ± 5.80 (60–80) 89.80 ± 7.84 (63–97) 0.001*
50th.min dex.infusion 68.12 ± 5.86 (60–79) 90.05 ± 6.81 (66–98) 0.001*
60th.min dex.infusion 69.45 ± 6.91 (62–80) 90.20 ± 6.45 (66–99) 0.001*
70th.min dex.infusion 67.50 ± 7.34 (62–81) 89.71 ± 7.78 (66–96) 0.001*
80th.min dex.infusion 71.20 ± 6.38 (64–79) 89.91 ± 8.21 (67–97) 0.005*
90th.min dex.infusion 73.67 ± 10.07 (66–85) 88.50 ± 11.45 (67–97) 0.070
* p < 0.05; significant difference between the groups.
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difference between the groups (p = 0.016). The mean
time of cessation of motor blockade was
106.40 ± 41.02 in Group I (43–215) and
90.50 ± 35.61 in Group II (52–190). Thus, there was
no statistically significant difference between the
groups in this aspect (p = 0.084).
The mean time to Bromage 3 was 11.03 ± 17.13 in
Group I (3–100) and 11.83 ± 5.33 in Group II (5–30).
There was a statistically significant difference between
the groups (p = 0.004) (Table 6).
The mean amnesia score before anesthesia was
6.00 ± 0.0 in Group I (6–6) and 6.00 ± 0.00 in Group
II (6–6). Thus, no statistically significant difference was
found between the groups in this aspect (p = 1.000).
The mean amnesia score after the administration of
anesthesiawas 3.30 ± 1.11 inGroup I (2–6) and 6.00 ± 0.00
in Group II (6–6). Thus, there was a statistically significant
difference between the groups in this aspect (p ≤ 0.001).
When the postoperative SAP values of the groups
were compared, there was a statistically significant
difference at postoperative 5, 15, and 30 min between
the groups (p < 0.001, p < 0.001, and p < 0.001,
respectively). The comparison of postoperative DAP
values between groups revealed a statistically signifi-
cant difference at postoperative 5, 15, and 30 min
(p < 0.001). With respect to the postoperative ABH
values of the two groups, there was a statistically
significant difference at postoperative 5 and 15 min
(p < 0.006 and p < 0.013, respectively) (Figures 1–3).
There was a statistically significant difference
between the groups at postoperative 30, 45, and
60 min and at postoperative 2, 4, 6, 12 and 24 h
with respect to postoperative SpO2 values
(p < 0.005, p < 0.004, p < 0.008, p < 0.008, p < 0.008,
p < 0.008, p < 0.008, and p < 0.011, respectively).
When the postoperative sedation scores of the
groups were compared, there was a statistically sig-
nificant difference at postoperative 5, 15, and 30 min
(p < 0.001, p < 0.001, and p < 0.011, respectively).
In terms of postoperative VAS scores of the groups,
a statistically significant difference was found at post-
operative 12 h (p < 0.045). Eleven patients in Group I
and 20 patients in Group II required additional analge-
sics. There was no statistically significant difference
between the groups with respect to postoperative
medication requirements (p = 0.092).
4. Discussion
Spinal anesthesia is a regional anesthesia technique
wherein local anesthetic is administered into the sub-
arachnoid space. The drug produces sympathetic sen-
sory or motor blockade depending on its dose,
concentration, and/or volume. It is widely preferred
in urologic interventions [9]. Spinal anesthesia has
been used as a popular method since 1970s. Spinal
anesthesia has various advantages such as enabling
the patient to be awake during the operation, con-
tinuation of spontaneous respiration, and protection
of reflexes such as swallowing and coughing. Other
advantages include early mobilization in the post-
operative period, prolonged postoperative analgesia,
low rates of respiratory complications, and shorter
length of hospital stay. However, patients who remain
awake throughout surgery may experience severe
stress and anxiety because they are aware of the
surgical process and fear that they might feel pain.
This undesired outcome is eliminated by sedating the
patients during the operation. Sedation is possible
through inhalation or bolus or continuous infusion
of pharmacological agents injected intravenously [10].
Sedation used to relieve mental and physical anxi-
ety depresses the relevant centers in the brain and
produces an altered mental state in a broad spectrum
from a fully alert state to unconsciousness depending
on the dose of the pharmacological agent adminis-
tered [11]. The primary risk of sedation is respiratory
depression; therefore, ECG and noninvasive blood
pressure of the patients should be monitored via
devices such as pulse oxymeters, and the anesthesiol-
ogist should establish a visual and/or verbal relation-
ship with the patient throughout the operation [12].
Fcarcsi et al. compared the sedative activity of and
hemodynamic responses to dexmedetomidine and
Table 5. Onset of sensory blockage, duration of sensory blockage, and mean time to achieve max. sensory blockage.
Onset of sensory blockage (min) Group I (n = 30) Group II (n = 30) p
Onset of the sensory blockage 2.90 ± 1.470 5.00 ± 2.665 0.001*
Duration of sensory blockage 131.77 ± 27.092 124.80 ± 26.779 0.478
Time to max. sensory blockage 11.30 ± 7.489 20.20 ± 37.991 0.007*
*p < 0.05; significant difference between the groups.
Table 6. Onset of motor blockage, duration of motor blockage, time to achieve Bromage III.
Timing (min) Group I (n = 30) Group II (n = 30) p
Onset of motor blockage 5.27 ± 3.503 8.83 ± 6.103 0.016*
Duration of motor blockage 106.40 ± 41.024 90.50 ± 35.618 0.084
Time to achieve Bromage III 11.03 ± 17.135 11.83 ± 5.331 0.004*
*p < 0.05; significant difference between the groups.
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midazolam administration in patients who underwent
cataract surgery under topical anesthesia [13]. They
divided the patients into two groups and administered
dexmedetomidine to Group I (loading dose of 1 μg kg−1
and maintenance dose of 0.05–0.7 μg kg−1 h−1 after
20 min) and midazolam to Group II (loading dose of
50μg kg−1 andmaintenance dose of 2.5–3.5μg kg−1 h−1)
by adjusting the infusion according to the Ramsay
Sedation Scale. In Group I, the mean pulse rate
decreased from 68 to 55, whereas in Group II, the
mean pulse rate decreased from 68 to 63. No hypoten-
sion or desaturation episodes or significant side effects
were observed in their patients. On the other hand,
dexmedetomidine group demonstrated faster post-
operative recovery. As a result, dexmedetomidine
group showed better patient compliance and sedation
level compared with midazolam group in cataract
surgery.
Another study evaluated the effects of dexmede-
tomidine and midazolam in children aged 1–7 years
via MRI with respect to their sedative, hemodynamic,
and respiratory effects. Following the loading dose,
dexmedetomidine infusion of 0.5 μg kg−1 h−1 was
administered to one group, whereas the other group
received midazolam infusion at a rate of 6 μg kg-
−1 min−1 following a loading dose of 0.2 mg kg−1.
The level of sedation was more satisfactory and
shorter in duration, and the analgesic requirement
was also lower in the dexmedetomidine group.
Furthermore, it was asserted that dexmedetomidine
provided improved sedation without causing hemo-
dynamic and respiratory effects [14].
Coşkuner et al. [15] in a study, following an injection of
patients with epidural anesthesia via bupivacaine, admi-
nistered dexmedetomidine infusion of 0.5 μg kg−1 h−1
throughout surgery, after an initial dose of 1 μg kg−1.
The researchers found that BIS scores were lower in this
group in the first 7 min compared with those in the
control group, and they reported that prolongedduration
of recovery from sensory blockade increased atropine
consumption related to bradycardia.
A study [Observer Assessment of Alertness/
Sedation] comparing the loading dose of dexmedeto-
midine 1 μg kg−1 followed by a maintenance dose of
0.4–0.7 μg kg−1 h−1 with a loading dose of propofol
75 μg kg−1 min−1 followed by a maintenance dose of
12.5–75 μg kg−1 min−1 evaluated the level of sedation
and BIS. The level of sedation was maintained at a BIS
value of 70–80. Although sedation was induced faster
with propofol and slower with dexmedetomidine, it
was indicated that the level of sedation was similar
after the first 25 min. It was determined that a dexme-
detomidine dose of 0.7 μg kg−1 h−1 was equivalent to a
propofol dose of 38 μg kg−1 min−1 [16].
The short half-life of dexmedetomidine ensures a
primary advantage in its use in sedation. In addition,
other superior characteristics include its analgesic
effect and maintenance of cardiorespiratory function.
During dexmedetomidine infusion, hypotension
and bradycardia may occur, particularly after the
administration of the loading dose. These cardiovas-
cular side effects can be reduced to a negligible level
by lowering the initial loading dose. When infusion is
discontinued, these levels increase slowly, and no
rebound cardiovascular effects and symptoms of
withdrawal syndrome are observed [17]. In the pre-
sent study, we found that systolic and diastolic arterial
pressures in the dexmedetomidine group that
received infusion at a rate of 0.2 μg kg−1 h−1 were
significantly lower than those in the control group
(p < 0.05). This result may be explained by the hypo-
tensive effect of dexmedetomidine. On the other
hand, despite the fact that there was a statistically
significant difference between the groups, no inter-
vention was required for reduced levels of arterial
pressure and ABH because they did not affect the
clinical conditions in the dexmedetomidine group. In
our study, the fact that we did not detect any signifi-
cant cardiovascular side effects may be related to the
lack of administration of loading dose.
Shehabi et al. [18] reported, on average, a 16%
decrease in SAP and a 21% decrease in ABH in 20
intensive care unit patients during dexmedetomidine
infusion that lasted 71.5 h (0.2–0.7 μg kg−1 h−1).
Santpur et al. [19] divided 60 patients who under-
went lower-extremity surgery into two groups, and
following spinal anesthesia, they administered dexme-
detomidine infusion at an initial dose of 1 μg kg−1 and
at a maintenance dose of 0.5 μg kg−1 h−1 after 20 min
to Group I. They administered saline infusion to Group
II and compared hemodynamic stability and the dura-
tion of spinal anesthesia. They concluded that intra-
venous dexmedetomidine infusion provided
hemodynamic stability and prolonged the duration
of spinal anesthesia.
In the study by Kang et al. [20], 74 patients under-
going spinal anesthesia for lower-extremity surgery
were divided into two groups. Patients in Group I
received an initial dexmedetomidine infusion at a
rate of 1 μg kg−1 for the first 10 min followed by a
maintenance infusion at a rate of 0.2 μg kg−1. Patients
in Group II received the same doses over the course of
5 min. Preoperative vital signs, anxiety, and patient
comfort were compared between the groups. As a
result, no statistically significant difference was
found between the groups in terms of bradycardia
and oxygen saturation. The level of anxiety and
patient comfort were also not different.
In the study by Yoon et al. [21], 90 patients under-
going spinal anesthesia were divided into two groups.
Patients in Group I received midazolam infusion with
a loading dose of 0.05 mg kg−1 over the course of
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10 min, followed by dexmedetomidine infusion at a
rate of 0.5 μg kg−1 h−1 within 10 min. Patients in
Group II received continuous dexmedetomidine infu-
sion following an initial dexmedetomidine dose of
0.5 μg kg−1 h−1 for 10 min. Consequently, bradycardia
was more frequent, and sedation was deeper in the
midazolam plus dexmedetomidine group.
Ahn et al. [22] used intravenous atropine injection
during premedication to avoid development of brady-
cardia as a side effect of dexmedetomidine used for
sedation purpose in patients administered spinal
anesthesia. In a group of 140 patients, they administered
dexmedetomidine infusion at a loading dose of 0.6 μg
kg−1 over the course of 10 min followed by a mainte-
nance dose of 0.25 μg kg−1 and atropine 0.5 mg follow-
ing the loading dose in Group I. Patients in Group II
received saline solution. There was no statistically sig-
nificant difference between the two groups with respect
to hypotension episodes, whereas bradycardia was fre-
quent in the group that received no IV atropine.
Hall et al. [23] studied seven healthy volunteers and
used dexmedetomidine at different infusion rates (0.2
versus 0.6 μg kg−1 h−1); they reported an increase in the
rate of ABH and a decrease inmean arterial pressure and
cardiac output with increasing infusion doses.
Although cardiovascular effects of dexmedetomi-
dine and morphine were parallel in the study by
Arain et al. [16], it was observed that ABH was sig-
nificantly lower in the dexmedetomidine group that
received infusion at a rate of 0.4 μg kg−1 h−1 following
a loading dose of 1 μg kg−1. In a different study by the
same researchers, dexmedetomidine was adminis-
tered using a same dosing protocol, and similar
results were obtained. These results were attributed
to the loading dose of dexmedetomidine [24].
In the present study, the mean time to onset of
sensory blockade and motor blockade and the mean
time to maximum sensory blockade were shorter in
the dexmedetomidine group. As a result, the initiation
of surgery was faster, and it was easier to administer
sufficient anesthesia. In a similar study, Agrawal et al.
[25] demonstrated that IV dexmedetomidine pro-
longed the duration of blockade in patients adminis-
tered spinal anesthesia.
Faraj et al. [26] conducted a similar study on 364
patients administered spinal anesthesia and found that
intravenous administration of dexmedetomidine pro-
longed the duration of sensory and motor blockade
and delayed the time to first analgesic requirement.
In our study, we monitored the depth of sedation
using BIS. The infusion rate was set so as to maintain a
BIS score between 60% and 80%. In many studies in the
literature [27–29], we observed that infusion rate is
adjusted to achieve a desired level of sedation. We
found that the infusion rate in dexmedetomidine group
was significantly lower than that in the control group in
the intraoperative period over the course of 90 min.
In the present study, we observed no excessive
sedation in any of the cases (BIS < 50%), and there
were no changes in respiratory rate or SpO2. In
another study reporting on volunteers who received
IV dexmedetomidine infusion for 24 h with a target
plasma concentration of 0.3–1.25 μg L−1, no respira-
tory depression was observed, and oxygen saturation
was maintained above 90% in all individuals [30]. One
of the limitations of our study was atropine midazo-
lam premedication. We used intramuscular atropine
to dry the secretions, help to produce bronchodilata-
tion, and prevent vasovagal reactions. It has superior
benefits with the use of dexmedetomidine. Other
future studies could be planned with other premedi-
cation agents.
Dexmedetomidine is an anxiolytic, hypnotic, seda-
tive, analgesic, and anesthetic agent that has no sig-
nificant depressive effect on the respiratory system.
5. Conclusions
In conclusion, the present study compared IV admin-
istration of dexmedetomidine with saline infusion in
urologic cases administered spinal anesthesia and
found that dexmedetomidine had intraoperative
depressive effects on hemodynamic parameters,
whereas we demonstrated that dexmedetomidine
improved the quality of motor and sensory blockade
and induced amnesia and sedation. Moreover, we
found that dexmedetomidine did not have prolonged
postoperative effects and did not reduce analgesic
requirements.
The authors of the present study conclude that intra-
venous dexmedetomidine infusion produces quality
sedation in patients administered regional anesthesia.
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